Analysis shows positive safety data for Tradjenta in T2D

Results from two post-hoc, pooled analyses of trials examining the safety of Tradjenta (linagliptin), from Boehringer and Eli Lilly, in adults with Type 2 Diabetes (T2D) shows a hypoglycemic incidence rate for linagliptin compared with placebo was 11.5 percent vs. 14 percent, respectively. Additionally, incidence of adverse events (AE) or serious adverse events (SAE) with linagliptin was similar to placebo (AE 56.5 percent versus 61.2 percent, and SAE 4.8 percent versus 6.3 percent, respectively).

The study used data from 22 linagliptin clinical trials with 7,400 adults with T2D (4,810 received linagliptin, 2,590 received placebo). Data were presented by Prof. Nikolaus Marx, Professor of Medicine and Cardiology, University Hospital of Aachen, Germany at the 49th Annual Meeting of the European Association for the Study of Diabetes.